Tivanidazole is metronidazole derivative. It is antiprotozoal drug. Tivanidazole was used as trichomonacide.

Edelfosine is a synthetic alkyl-lysophospholipid, a potent immunomodulator and an effective inhibitor of tumor cell proliferation. The cytotoxic effect of edelfosine has been evaluated in a large variety of both tumor (leukemic and solid) and normal cell types, showing a high degree of selectivity towards tumor cells. Like all alkyl-lysophospholipids, Edelfosine incorporates into the cell membrane and does not target the DNA. In many tumor cells, Edelfosine causes selective apoptosis, sparing healthy cells. Edelfosine can activate the Fas/CD95cell death receptor, can inhibit the MAPK/ERK mitogenic pathway and the Akt/protein kinase B (PKB) survival pathway. Edelfosine apoptosis-inducing abilities were studied with several types of cancer, among them multiple myeloma and non-small and small cell lung carcinoma cell lines. In vivo activity against human solid tumors in mice was shown against malignant gynecological tumor cells, like ovarian cancer, and against breast cancer. In vivo biodistribution studies demonstrated a “considerably higher” accumulation of Edelfosine in tumor cells than in other analyzed organs. Several clinical trials were conducted. Among them, a phase I trials with solid tumors or leukemias and phase II with non-small-cell lung carcinomas (NSCLC). In Phase II clinical trial for use of Edelfosine in treating leukemia with bone marrow transplants, it was found to be safe and 'possibly effective'. A phase II trial for the treatment of brain cancers was also reported. It showed encouraging results in stopping the growth of the tumor and a considerable improvement in the “quality of life” of the patients. A phase II trial on the effect of Edelfosine on advanced non-small-cell bronchogenic carcinoma had a “remarkable” “high proportion of patients with stationary tumor status” as result, stable disease after initial progression in 50% of the patients.

Antafenite is an anthelminthic drug.

Antazonite (R 6438) is an anthelmintic agent. When given orally to chickens in a dose of 160 mg/Kg body weight, all Ascaridia sp., all Hetevakis sp., and about 30% Capillaria sp. are expelled within 48 hr. It is supposed that the anthelmintic activity of Antazonite is due to its major metabolite, R 8141. R 6438 is active as an anthelmintic in poultry, but not in rats. Its metabolite, R 8141, is active in both species.

Metronidazole phosphate is a water-soluble prodrug of metronidazole.

Menoctone is a potent liver-stage antimalarial with corresponding erythrocytic stage efficacy. This drug is an effective treatment against Theileria parva, a parasitic protozoan that causes East Coast fever in cattle. Menoctone most likely targets the mitochondrial respiration chain of Plasmodium.

Clioxanide is a derivative of diiodobenzanilide, developed by Parke, Davis & Co in the 1960s. It was used as an antihelmintic against Fasciola hepatica and Haemonchus contortus. In sheep, the compound was demonstrated high efficiency (greater than 90%) when administered at 20-40 mg/kg. Later it was found that clioxanide is an inhibitor of Type III Secretion in Yersinia bacteria.

Parbendazole is a potent inhibitor of microtubule assembly that was studied as an anthelmintic agent. Information about the current use of this drug is not available.

Dimetridazole is an anti-fungal and anti-protozoal drug traditionally used in veterinary for the prevention and treatment of histomoniasis in turkeys, genital trichomoniasis in cattle and hemorrhagic enteritis in pigs. Results from the in vitro and in vivo tests suggested, that dimetridazole was not genotoxic compound, but its use is legally limited, although this compound is still can be found in eggs.